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Abstract
Indwelling pleural catheters (IPC) are now being considered worldwide for 
patients with recurrent pleural effusions. It is commonly used for patients with 
malignant pleural effusions (MPE) and can be performed as outpatient based day 
care procedure. In malignant pleural effusions, indwelling catheters are particu-
larly useful in patients with trapped lung or failed pleurodesis. Patients and care 
givers are advised to drain at least 3 times a week or in presence of symptoms i.e. 
dyspnoea. Normal drainage timing may lasts for 15–20 min which subsequently 
improves their symptoms and quality of life. Complications which are directly 
related to IPC insertion are extremely rare. IPC’s are being recently used even for 
benign effusions in case hepatic hydrothorax and in patients with CKD related 
pleural effusions. Removal of IPC is often not required in most of the patients. It 
can be performed safely as a day care procedure with consistently lower rates of 
complications, reduced inpatient stay. They are relatively easy to insert, manage and 
remove, and provide the ability to empower patients in both the decisions regarding 
their treatment and the management of their disease itself.
Keywords: indwelling pleural catheters, recurrent pleural effusion, malignant 
effusion, pleurodesis
1. Introduction
Indwelling pleural catheters (IPC) are now being considered worldwide for 
patients with recurrent pleural effusions [1]. It is commonly used for patients with 
malignant pleural effusions (MPE) and can be performed as outpatient based 
day care procedure. Talc pleurodesis and indwelling pleural catheters are the 
standard of care therapeutic options for the patients presenting with symptomatic 
malignant pleural effusions. In malignant pleural effusions, indwelling catheters 
are particularly useful in patients with trapped lung or failed pleurodesis. IPCs 
are effective, both in terms of symptom control and costs, and can dramatically 
improve the quality of life for patients who have traditionally needed lengthy 
hospital admissions.
2. Background
Indwelling pleural catheter (IPC) is a multi-fenestrated flexible silicone elas-
tomeric chest drain with a polyester cuff which envelops the medial portion of the 
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tube. The proximal end of tube has a one-way access valve designed to be attached 
to vacuum drainage bottles. Its distal part is tunneled through the subcutaneous 
tissue before placing it in the pleural space (Figure 1). Most widely used IPCs are 
pleurx catheter and IPC by Rockett medical. Pleurx catheter was approved by 
FDA in 1997 for patients with symptomatic malignant pleural effusions to relieve 
Dyspnea [2].
Before the advent of IPCs, conventional method for managing recurrent pleural 
effusions is to place a large bore chest drain with pleurodesis/multiple pleural aspi-
rations. Some centers were able to offer more invasive procedures, such as parietal 
pleurectomy or pleuro-peritoneal shunting, but these inevitably carried a risk of 
morbidity and were limited to patients who were fit enough to undergo general 
anesthesia [3, 4].
3. History of indwelling pleural drains
A widely recognized precursor to indwelling pleural catheter was first 
described in 1994. Robinson et al. [5] treated 9 patients with recurrent MPE, who 
had previously failed pleurodesis, with a Tenckhoff catheter, which was tunneled 
into the pleural space under local anesthesia. Implantable Porta cath was also 
used in olden days for some patients for intrapleural immunotherapy used in 
mesothelioma [6].
4. Indications
• Recurrent pleural effusion predominantly due to malignant etiology.
• Trapped lung with symptomatic pleural effusions.
• Recurrent pleural effusion due to benign etiologies such as hepatic hydrotho-
rax [7], chylothorax [8], CKD related effusions, loculated effusions [9], and 
empyema [10].
Figure 1. 





• Inability for the patient and care givers to handle or tolerate the drain.
• Significant coagulopathy.
• Parapneumonic effusion/empyema.
• Local cellulitis in the insertion site.
• Track metastasis over the proposed insertion site.
• Individuals in immunocompromised state due to systemic diseases.
6. IPC insertion
Most of this procedure can be performed as a day care procedure in outpatient 
settings. There is no need to admit the patient for IPC insertion unless clinically 
warranted. It is advisable to stop antiplatelet/antithrombotic medications before 
the procedure to minimize the risk of bleeding (Aspirin-withheld for 5 days, 
Clopidogrel—withheld for 7 days. IPC can be inserted in any position which is 
suitable for drainage. It is preferable to moniter his oxygen saturation and vitals 
during the procedure. Supplemental oxygen can be given to those patients who are 
dyspneic with hypoxemia. We often prefer to give supplemental oxygen to all our 
patients during the procedure.
It can be performed under conscious sedation with local anesthesia. The patient 
is typically placed in the lateral decubitus position, with the patient lying on the 
side contralateral to the effusion, although they can be inserted in other patient 
positions. Bedside ultrasound thorax is to be done which facilitates the site of entry 
and also helps to quantify the pleural effusion.
Under aseptic precaution, after local anesthetic (Lignocaine 1–2%) infiltration, two 
small incision are made, one at the pleural insertion point and another one 7–10 cm 
anterior to this, which will form the proximal end to the tunneled track. The IPC 
catheter is tunneled along this track with the pro-fibrotic cuff which promotes tissue 
growth and keeps the drain in-situ, situated approximately a third along the track.
The distal end of the catheter is then inserted into the pleural cavity, using the 
Seldinger technique. The incisions are then sutured closed, although the catheter 
itself is not sutured in place. A one-way valve on the external end is then attached to 
a drainage bag or vacuum bottle system.
7. Drainage
Patients and care givers are advised to drain at least 3 times a week or in presence 
of symptoms i.e. dyspnoea. Normal drainage timing may lasts for 15–20 min which 
subsequently improves their symptoms and quality of life. Drainage bottles are 
commercially available which are connected to proprietary one-way access valve on 
the external portion of the drain. Training to the patients and their family members 
has to be done for proper dressing and drainage by connecting the bottles with 
aseptic precautions. This drainage bottle is primed with a vacuum (Figure 2) in 
order to draw out the pleural fluid usually to a maximum of 1000 ml.
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8. Complications
Complications which are directly related to IPC insertion are extremely rare [11].
9. Immediate complications
It is common to see a small pneumothorax in the post procedure chest X ray as a 
result of air being drawn into the chest during insertion. Such appearances may also 
be produced by trapped lung if significant volumes of fluid have been removed or 
trapped lung itself is seen in 20–30% of patients with malignant pleural effusion.
Large significant pneumothorax should prompt consideration of Iatrogenic 
injury to underlying lung and may warrant an extended period of observation 
before discharge.
Subcutaneous emphysema is also been documented post procedure. This 
demonstrates another reason why careful consideration should be given to track 
length, as if it is made too long there is the possibility of a fenestration remaining in 
the extrapleural space.
Post procedure pain can be seen in significant number of patients which can 
be usually managed with analgesics. Severe pain and discomfort should prompt 
concerns over irritation or damage to intercostal nerves. Patient may experience 
pain and discomfort at the end of drainage which indicates complete drainage of 
the pleural space which is often seen in those with underlying trapped lung. Wound 
Dehiscence in IPC is rarely reported.
10. Late complications
Initially there was a concern surrounding the risk of associated infections with 
indwelling pleural catheters. However, data from the observational and random-






with one large multicenteric multinational retrospective study of over a 1000 
patients, demonstrating a 4.8% IPC-related pleural infection rate [12]. Common 
organisms implicated are Pseudomonas aeruginosa, Staphylococcus aureus, and 
Enterobacteriaceae which differ from the pattern what we usually expect in parap-
neumonic effusions [12].
Usually the infectious complications are reported after 6 weeks after the inser-
tion of IPC which indicates they are not secondary to the insertion but due to 
later spread of pathogens from the patient’s skin or lung parenchyma [13]. Proper 
care, IPC dressing and drainage techniques would help to minimize the risk. 
Reassuringly, the mortality rate from IPC-related infection is low (0.29%) and 
most of these patients can be managed with oral antibiotics [12]. There is no need 
to remove IPC as most patients responds very well to the therapy. If this approach is 
unsuccessful, then patient may require hospital admission for intravenous antibiot-
ics and placing the catheter on continuous free-drainage to facilitate resolution of 
the infection. In case of loculated pleural effusions, Intrapleural thrombolytics like 
tissue plasminogen activator and DNAase can also be given via IPC [13].
In malignant pleural effusion insertion of IPC may lead to track metastasis 
usually occurs in malignant mesothelioma [14]. Reported cases in the literature are 
sparse, but the incidence of metastasis occurring appears to be just below 1% [15]. 
Diagnosis can be made clinically or using ultrasound-guided biopsy [16], followed 
by prophylactic radiotherapy to prevent track metastasis. There is nothing to suggest 
that radiotherapy damages the IPC [14] and treatment, based upon small case series, 
tends to be successful, obviating the need for drain removal [17].
IPC blockage is another concern one need to consider since patency of the tube is 
important for effective drainage. This can be managed by daily saline flushing and 
on rare occasions in presence of thick loculated collection, one may use intrapleural 
fibrinolytics. The loss of electrolytes, immune factors or proteins has occasionally 
been raised as a concern of the long-term use of IPCs [18].
Catheter fracture is rare and may occur when an IPC is removed. The polyester 
cuff promotes inflammation and fibrosis which leads to tight anchoring of the 
catheter makes it difficult to remove. The risk of catheter fracture is reported to 
be about 10% [19]. This is usually managed by surgical exploration or just leaving 
the catheter fragments inside the body. No complications have been reported from 
retained fragments of IPC.
11. Use of IPC in malignant pleural effusions (MPE)
Conventional approach to the patients with symptomatic MPE is therapeutic 
pleurocentesis and subsequent pleurodesis. Various pleurodesis agents can be used 
but the most commonly used agent is talc which can be guided by thoracoscopic talc 
poudrage or instillation via standard chest tube. Option of IPC insertion is given 
to the patients who had developed trapped lung. IPCs are the ideal way for pallia-
tive care as they can be sited easily and quickly, and can be drained as often as is 
required to alleviate symptoms, allowing for consistent improvement in the breath-
lessness which will afflict the vast majority of patients with a malignant effusion 
[20] and improvements seen even in those with trapped lung [21].
Davies et al. [22] compared the use of IPCs to standard talc slurry via chest 
drain in patients who had not previously undergone pleurodesis. The trial used 
self-reported dyspnoea scores as its main outcome measure, showing that 6 weeks 
after randomization there was no significant difference between the two treatment 
arms. Some of the secondary endpoints appeared more favorable in the IPC group, 
including the proportion of patients who achieved a clinically significant relief 
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in their symptoms (86 vs. 74%); the median length of initial hospital stay (0 vs. 
4 days), and the median number of days spent in hospital for drainage over the fol-
lowing 12 months (1 vs. 4.5 days). Eventhough the study is underpowered, similar 
findings were reported elsewhere. Intrapleural Fibrinolytics can also be guided with 
IPC in case of multiloculated/septated effusion.
It also holds the potential to allow direct anti-cancer therapy. Sterman et al. 
[23] showing that patients with MPE or mesothelioma can be safely given both 
single- and repeated-dose interferon-β gene therapy and another group report-
ing the administration of monthly rituximab via an IPC for a patient with non-
Hodgkin’s lymphoma [24]. Jones et al. [25] and Rahman et al. [26] studied the use 
of Docataxel and Lipotechoic acid -T via IPC (Pleurx) respectively with favorable 
clinical response.
IPC can be combined with pleurodesis agents to achieve higher success rates and 
early pleurodesis in patients with high output effusion. Tremblay et al. [27] have 
demonstrated that low-level, repeated doses of intrapleural silver nitrate in a rabbit 
model can maintain the pleurodesis efficacy of a drug without raising the side 
effect profile. Dierdre B Fitzgerald et al. studied the use of talc via IPC with malig-
nant pleural effusion and concluded that IPC combined with inpatient talc slurry 
pleurodesis, followed by daily home drainage provided good success rates [28].
12. Spontaneous pleurodesis
Spontaneous pleurodesis is also possible in patients with IPC which is an added 
advantage. In a study by Yuvarajan et al. [29] Spontaneous pleurodesis was achieved 
in 55% of the patients with hepatic hydrothorax who were placed on IPC. Mean 
time for spontaneous pleurodesis is around 120.8 days. Collated data from various 
studies suggest an overall spontaneous pleurodesis rate of around 45% for patients 
with MPE [15], however, some studies have reported significantly higher [30, 31] or 
lower values [32]. Higher pleurodesis rates, often exceeding 70%, have been noted 
when more aggressive drainage regimens (daily or more frequent) have been used, 
or when patients undergo a talc pleurodesis at the same time as IPC insertion [31].
13. Impact of chemotherapy in patients with IPC
Usage of IPC significantly improves the dyspneoa, quality of life and their 
performance status which is crucial for initiating chemotherapy, as chemotherapy 
is usually deferred in patients with poor performance status. In spite of this, there 
is huge concern in the risk of infectious complications post chemotherapy in those 
patients with IPC. There was no difference in the pleural infection rates in a retro-
spective analysis of 170 patients who were receiving chemotherapy with IPC when 
compared to those patients who did not receive chemotherapy [33]. But the decision 
to place an IPC in those who is already on chemotherapy needs multidisciplinary 
discussion with oncologist, oncosurgeon, pulmonologist and infectious disease 
specialist.
14. IPC in benign effusions
The most common causes for nonmalignant pleural effusions are Parapneumonic 
effusions, effusions due to congestive heart failure (CHF), hepatic hydrothorax 




being recently used even for benign effusions in case hepatic hydrothorax and in 
patients with CKD related pleural effusions. Yuvarajan et al. [29] did a retrospective 
analytical study on the use of IPC in hepatic hydrothorax. 30 patients with hepatic 
hydrothorax were placed with indwelling pleural catheters. Spontaneous pleurodesis 
was achieved in 18 patients (60%) and IPCs were removed in these patients. Most 
of the patients (70%) who achieved spontaneous pleurodesis with IPC received at 
atleast one TIPS (Transjugular Intrahepatic porto systemic shunt) procedure. Mean 
time in which pleurodesis achieved was 120.8 days (range, 15–290 days). Thus TIPS 
procedure increases the success rate of pleurodesis with indwelling pleural catheters 
in hepatic hydrothorax.
IPC placement may be a reasonable clinical option for patients with refractory 
HH, but it is associated with significant adverse events in this morbid population. 
Potechin et al. [34] did a cohort study on IPC usage in patients who presented with 
recurrent effusion in end stage renal disease and concluded that IPC insertion for 
pleural effusions associated with end-stage renal disease appears safe and effective.
15. IPC removal
Removal of IPC is often not required in most of the patients. However, sponta-
neous pleurodesis is one of the potential causes for considering its removal. Other 
indications include pleural sepsis, nonfunctional/defective IPC and Severe pain with 
local cellulitis which cannot be managed with conservative approach. Removing 
indwelling pleural catheter is not an easy task. Since the polyester cuff attached to 
the drain is designed to promote local fibrosis and the removal of a drain can become 
more difficult with long standing IPC. In addition, advanced malignancy promotes 
ingrowth of fibrotic strands into the fenestrations of IPC further making the 
extraction of catheter difficult. For removal, one need to do careful and meticulous 
dissection of the fibrous material around the cuff following appropriate incisions. In 
those circumstances of difficulty in removal of IPC, an alternative is to simply leave 
the drain and to remove only the proximal portion. Fysh et al. [35] described 2 cases 
of this being undertaken in a small series of complicated removals. In none of the 
cases in which tubing was left intrapleurally did the patient experience any infective 
or pain-related complications during follow-up.
16. Conclusion
So IPCs plays a major role in patients with recurrent pleural effusions especially 
malignant pleural effusions. It is particularly useful in palliative care of the patients 
with trapped lung and failed chemical pleurodesis. It can be performed safely as a 
day care procedure with consistently low rates of complications, reduced inpatient 
stay and the recognition that significant improvements in patients’ symptoms. 
They are relatively easy to insert, manage and remove, and provide the ability to 
empower patient’s in both the decisions regarding their treatment and the manage-
ment of their disease itself.
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